Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of AZD1722 for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Oct 2023
Price :
$35
*
At a glance
- Drugs Tenapanor (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- Sponsors Ardelyx
- 23 Oct 2023 According to Ardelyx media release, data from this study presented at the American College of Gastroenterology (ACG) annual meeting,
- 23 Oct 2023 Results published in the Ardelyx Media Release
- 28 Feb 2017 Results assessing safety and efficacy of tenapanor, published in the American Journal of Gastroenterology